Efficacy of BAL5788, a prodrug of cephalosporin BAL9141, in a mouse model of acute pneumococcal pneumonia.
about
Ceftobiprole for the treatment of pneumonia: a European perspectiveCeftobiprole medocaril in the treatment of hospital-acquired pneumoniaMethicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odysseyIn vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureusResistance and the management of complicated skin and skin structure infections: the role of ceftobiprole.Ceftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia.In vitro and in vivo intracellular killing effects of tigecycline against clinical nontyphoid Salmonella isolates using ceftriaxone as a comparator.Emerging agents to combat complicated and resistant infections: focus on ceftobiproleProbability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects.Efficacy of ceftobiprole Medocaril against Enterococcus faecalis in a murine urinary tract infection modelInvestigational new drugs for the treatment of resistant pneumococcal infections.Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria.Pharmacodynamic characterization of ceftobiprole in experimental pneumonia caused by phenotypically diverse Staphylococcus aureus strainsAnti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy.In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection modelsCeftobiprole: first cephalosporin with activity against methicillin-resistant Staphylococcus aureus.Ceftobiprole: a new cephalosporin for the treatment of skin and skin structure infections.Exposure to ceftobiprole is associated with microbiological eradication and clinical cure in patients with nosocomial pneumonia.Pharmacokinetic and pharmacodynamics evaluation of ceftobiprole medocaril for the treatment of hospital-acquired pneumonia.Evaluation of ceftobiprole activity against a variety of gram-negative pathogens, including Escherichia coli, Haemophilus influenzae (β-lactamase positive and β-lactamase negative), and Klebsiella pneumoniae, in a rabbit meningitis model.Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus.Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin.Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis.Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin.Efficacies of ceftobiprole medocaril and comparators in a rabbit model of osteomyelitis due to methicillin-resistant Staphylococcus aureus.Protein-inspired antibiotics active against vancomycin- and daptomycin-resistant bacteria.
P2860
Q26796463-63DC705E-AD09-4AC2-A898-358F0778F1B1Q28085517-170722E3-07E0-41A8-ABCD-F979819EE74FQ28235095-7E6DF823-2EDD-4562-81C9-EE8193A3258EQ33559139-1D02D639-670A-4E21-9EDE-743B381E1AA3Q33935282-A6FE34A0-57F1-43EF-BF0F-1D70D48C6452Q34187667-4639BD2B-6AAE-4CE2-B3A8-680D1899A962Q34433342-E44AA7E0-0F86-4BA2-BC37-3011D56A37ACQ35005056-01F1EA55-451D-477C-9451-E5F9938B1510Q35026567-EBE89811-7547-4088-BCF4-FB6B1043B5DBQ35879080-BB92D9FB-7363-4B5E-B08B-B5BB3232984DQ36018587-9F8D94B0-AD71-4C4B-969C-CA80A3EB6A70Q36210902-3D79E84D-B68C-46C8-986D-4F4F502AB88CQ36422630-D668CD5D-8D8A-45D0-B3FE-170930DBB261Q36744877-F7FC25F2-B7BC-4DB0-9AC5-FFC6087625CEQ36763997-2CD64D38-E083-44A8-B647-9776AC109459Q36932924-5531A8AC-D893-47C9-95EF-6DA2F0FB58D0Q37461413-9F20D767-4DB7-4F61-AD91-0EB0EFEFBAE7Q37593094-0C9897D0-CA26-433F-AA81-9942B5FC2571Q37713040-3B0B96CE-8765-40E8-A875-F92D8FB8965AQ38099393-78117F42-A0D2-41A2-A0DC-1F334180D4DEQ40600643-3941997D-BE0D-4108-9706-00D57D3D6405Q41092910-A15D90FC-A59E-4CB6-A581-1FCC99B1DCAEQ41847350-E857E68F-175D-4161-8B69-A9C23E3F991AQ41849670-BB186155-3C78-44AA-B618-4E24050C0439Q42112713-E13C6AF2-CBD0-4B64-947F-E3E4907B5BB9Q43183402-10B29F85-AD49-4592-AA32-89FF2058DA34Q47236751-0245DD1D-8A38-470D-ABE1-C9C4CF933B32
P2860
Efficacy of BAL5788, a prodrug of cephalosporin BAL9141, in a mouse model of acute pneumococcal pneumonia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2004
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Efficacy of BAL5788, a prodrug ...... acute pneumococcal pneumonia.
@en
Efficacy of BAL5788, a prodrug ...... acute pneumococcal pneumonia.
@nl
type
label
Efficacy of BAL5788, a prodrug ...... acute pneumococcal pneumonia.
@en
Efficacy of BAL5788, a prodrug ...... acute pneumococcal pneumonia.
@nl
prefLabel
Efficacy of BAL5788, a prodrug ...... acute pneumococcal pneumonia.
@en
Efficacy of BAL5788, a prodrug ...... acute pneumococcal pneumonia.
@nl
P2093
P2860
P1476
Efficacy of BAL5788, a prodrug ...... acute pneumococcal pneumonia.
@en
P2093
Azoulay-Dupuis E
Schleimer M
Schmitt-Hoffmann A
P2860
P304
P356
10.1128/AAC.48.4.1105-1111.2004
P407
P577
2004-04-01T00:00:00Z